ABVC Biopharma Inc
NASDAQ:ABVC
Net Margin
ABVC Biopharma Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
51.8m USD |
-781%
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
164.6B USD |
3%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
98.2B USD |
9%
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
88.3B Zac |
69%
|
|
| US |
|
Coupang Inc
F:788
|
43.8B EUR |
1%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
44.7B USD |
-39%
|
|
| US |
R
|
Reddit Inc
NYSE:RDDT
|
40.9B USD |
13%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
32.2B CHF |
8%
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
630.2T IDR |
1%
|
|
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
31.5B USD |
-9%
|
ABVC Biopharma Inc
Glance View
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ABVC Biopharma Inc's most recent financial statements, the company has Net Margin of -781.1%.
You don't have any saved screeners yet